|
Cancer is a complex disease which is caused by multiple genetic and epigenetic changes. In addition, cancer is a genetic moving target capable of mutating into resistant or more aggressive forms. Prof Liu’s team have employed a strategy of using genomic data to reconstruct systems maps of critical regulatory networks, identify critical nodes in the oncogeneic network and target them in order to induce apoptosis and cell differentiation. This genome-to-system approach was used to quickly uncover the complex mechanisms of action of DZNep, an S-adenosylhomocysteine hydrolase inhibitor that induces apoptosis in cancer cells but not in normal cells. Prof Liu explains how EZH2 levels and genomic mapping will be used to decide patient eligibility for this treatment and notes that considering this therapy targets a process rather than a specific cancer; it will be useful when treating a number of different cancers.
|
Video Length: 0
Date Found: December 28, 2010
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|